SNAP 94847 is a novel, high affinity selectivemelanin-concentrating hormonereceptor1 (MCHR1)antagonist with (K_i= 2.2 nM,K_d=530 pM), it displays >80-fold and >500-fold selectivity over MCHα1A andMCHD2 receptors respectively. SNAP 94847 binds with high affinity to the mouse and ratMCHR1with minimal cross-reactivity to other GPCR, ion channels, enzymes, and transporters^[1][3].

Ki: 2.2 nM (MCHR1); Kd: 530 pM (MCHR1)^[1]

SNAP 94847 (oral gavage; 20 mg/kg; 14 days) shows an exaggerated locomotor response to acute quinpirole [treatment: F(2,19)=11.31, treatment × time: F(34,323) = 4.061], the effect of SNAP 94847 on quinpirole-evoked ambulations over the entire observation period is significant compared to the untreated animals^[2].
SNAP 94847 (oral administration; 20 mg/kg; 21 days) in drink water, produces a significant increase in ambulation relative to untreated animals [treatment: F(3,28) = 8.971; treatment × time: F(51,476)=11.50]. shows a marked increase in locomotion is apparent after 40 min in the SNAP 94847-treated group,this effect is significant over 180 min^[2].
SNAP 94847 (oral administration; 10 mg/kg), has a good bioavailability (59%), low plasma and blood clearances of 4.2 L/hr/kg and 3.3 L/hr/kg, respectively, and the half-life was shown to be 5.2 h in rats in a PK study^[3].

478.57

C₂₉H₃₂F₂N₂O₂

487051-12-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.